This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.
General Information
Mouse: CB57BL/6 x B6C3H
Conditional expression of the human wild type alpha-synuclein protein under the control of the Calcium/calmodulin-dependent protein kinase IIa promoter (CaM) and the tetracycline-regulated tet-off system (tTA).
Endogenous alpha synuclein: Yes
Corresponding human genotype: Autosomal dominant mutation in PD patients (PARK1/PARK4)
Transgene insertion: not specified
References: Nuber 2008, Lim 2010
Transgene expression
- Expression of human alpha-synuclein is observed in forebrain and midbrain with 1-3 x increase compared to littermate wild type mice.
- Expression of human alpha-synuclein can be blocked by giving mice doxycycline in drinking water (Nuber 2008) or chow (Lim 2010)
Neurodegeneration
- P21: Atrophy in post mitotic DG hippocampal neurons is observed.
- 9 months: Very moderate, but not statistically significant, loss of TH-positive neurons (around 15%) is detected compared to control mice
Dopamine Homeostasis
- 25 months: a decrease in DA levels is observed in the olfactory bulb; some reduction is also detected in the SN but does not reach statistical significance.
Inclusions
- No inclusions are observed at any time points in this model
- 12 and 18 months: high cytoplasmic expression of hsynwt protein in the SN is observed
Motor Behaviours
- 30 weeks: start of progressive motor decline is observed. This deficit can be reduced, in aged-animals 8(58 weeks-old) by giving mice doxycycline which prevents human alpha-synuclein over-expression
Response to L-DOPA treatment
- Not reported
Non motor Behaviours
- 12 months : some alterations in long term memory and spatial learning, assessed by the Morris Water Maze, are observed compared to wild type littermates
Electrophysiology
- Not reported
Neuroinflammation
- Not reported